Related Experiment Video
Updated: Apr 1, 2026
Whole-cell MALDI-TOF Mass Spectrometry is an Accurate and Rapid Method to Analyze Different Modes of Macrophage Activation
Published on: December 26, 2013
Macrophage Activation Syndrome
Angelo Ravelli1, Sergio Davì2, Francesca Minoia2
1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Head, Center of Rheumatology, University of Genoa and G. Gaslini Institute, via G. Gaslini 5, Genoa 16147, Italy.
Abstract:
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of rheumatic disorders that occurs most commonly in systemic juvenile idiopathic arthritis. In recent years, there have been several advances in the understanding of the pathophysiology of MAS. Furthermore, new classification criteria have been developed. Although the place of cytokine blockers in the management of MAS is still unclear, interleukin-1 inhibitors represent a promising adjunctive therapy, particularly in refractory cases.
Insights
Macrophage activation syndrome (MAS), a severe complication of rheumatic diseases like systemic juvenile idiopathic arthritis, is better understood. Interleukin-1 inhibitors show promise as adjunctive therapy for difficult MAS cases.
Area of Science:
- Rheumatology
- Immunology
- Pediatric Rheumatology
Background:
- Macrophage activation syndrome (MAS) is a critical, life-threatening condition.
- It frequently complicates systemic juvenile idiopathic arthritis (sJIA).
Purpose of the Study:
- To review recent advances in understanding MAS pathophysiology.
- To discuss new classification criteria for MAS.
- To evaluate potential therapeutic strategies for MAS.
Main Methods:
- Literature review of recent research on MAS.
- Analysis of new diagnostic and classification criteria.
- Assessment of current and emerging treatment options.
Main Results:
- Significant progress has been made in elucidating the pathophysiology of MAS.
- Novel classification criteria for MAS have been established.
- Interleukin-1 inhibitors are emerging as a potential adjunctive treatment.
Conclusions:
- MAS understanding has advanced, aiding diagnosis and management.
- Interleukin-1 inhibitors offer a promising therapeutic avenue for refractory MAS.
- Further research is needed to clarify the role of cytokine blockers in MAS management.
